We Think Lee's Pharmaceutical Holdings' (HKG:950) Profit Is Only A Baseline For What They Can Achieve

Investors were underwhelmed by the solid earnings posted by Lee's Pharmaceutical Holdings Limited (HKG:950) recently. We did some digging and actually think they are being unnecessarily pessimistic.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

The Impact Of Unusual Items On Profit

For anyone who wants to understand Lee's Pharmaceutical Holdings' profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by HK$26m due to unusual items. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual expenses don't come up again, we'd therefore expect Lee's Pharmaceutical Holdings to produce a higher profit next year, all else being equal.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Lee's Pharmaceutical Holdings.

Our Take On Lee's Pharmaceutical Holdings' Profit Performance

Unusual items (expenses) detracted from Lee's Pharmaceutical Holdings' earnings over the last year, but we might see an improvement next year. Based on this observation, we consider it likely that Lee's Pharmaceutical Holdings' statutory profit actually understates its earnings potential! And the EPS is up 55% over the last twelve months. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. For example, we've found that Lee's Pharmaceutical Holdings has 2 warning signs (1 can't be ignored!) that deserve your attention before going any further with your analysis.

Today we've zoomed in on a single data point to better understand the nature of Lee's Pharmaceutical Holdings' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.